Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Professor at Tianjin University of Traditional Chinese Medicine, China

Professor Haiyang Yu is an accomplished researcher and academic in the field of pharmacology and traditional Chinese medicine. With a focus on the anti-tumor molecular mechanisms of natural products, he has significantly contributed to cancer research. His work delves into understanding how small molecules in traditional Chinese medicine and other natural sources can target cancerous cells. Throughout his career, Professor Yu has gained recognition for his work, publishing over 40 peer-reviewed articles, including in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology. He has also led six national research projects. His lab at Tianjin University of Traditional Chinese Medicine explores the pharmacological potential of these compounds, using network pharmacology to identify new drug targets and elucidate the molecular mechanisms behind anti-tumor effects. His research has the potential to transform cancer treatment by merging the ancient wisdom of TCM with modern scientific methods.

Professional Profile

Education

Professor Haiyang Yu holds a Ph.D. from Dong-a University, where he honed his academic foundation in pharmacology and molecular biology. After earning his doctoral degree, he pursued postdoctoral research training from 2012 to 2014, furthering his expertise in the molecular mechanisms of disease and drug discovery. This rigorous academic journey provided him with the necessary skills to embark on significant research in cancer pharmacology. His educational background underscores his commitment to advancing scientific knowledge, particularly in integrating traditional medicine with modern pharmacological practices. Professor Yu’s academic credentials have shaped him into a leader in his field, allowing him to explore novel therapeutic pathways for cancer treatment through natural products and traditional Chinese medicine.

Professional Experience

Currently serving as a professor at Tianjin University of Traditional Chinese Medicine, Professor Haiyang Yu has built a distinguished career. His position allows him to influence the next generation of researchers while continuing his own innovative work. His research is primarily concerned with the anti-tumor effects of natural products, an area in which he has published extensively. He has presided over six national projects, demonstrating his leadership capabilities and ability to secure funding for significant research initiatives. Prior to this, Professor Yu gained invaluable postdoctoral experience, expanding his research scope and applying his findings in practical settings. His experience includes collaborations with international researchers, which further enhances his ability to contribute to the global understanding of cancer pharmacology. Throughout his career, Professor Yu has successfully blended traditional Chinese medicine and contemporary research techniques, achieving breakthroughs that have had an impact on both scientific and medical communities.

Research Interests

Professor Haiyang Yu’s research primarily focuses on network pharmacology, natural products, traditional Chinese medicine (TCM), and cancer drug discovery. His interest lies in uncovering the molecular mechanisms by which natural compounds, especially those derived from TCM, exhibit anti-cancer properties. By employing advanced techniques in network pharmacology, Professor Yu investigates how these compounds interact with specific drug targets to inhibit cancer cell growth. His lab’s research aims to explore novel drug targets that could lead to more effective cancer therapies. A key part of his research involves exploring the synergy between traditional Chinese medicine and modern pharmacological methods, bridging ancient knowledge with cutting-edge technology. This interdisciplinary approach is central to his work, providing new avenues for the development of cancer treatments and potentially improving the effectiveness of existing therapies.

Research Skills

Professor Haiyang Yu’s research skills encompass a broad array of advanced techniques in pharmacology, molecular biology, and bioinformatics. His expertise in network pharmacology enables him to explore the complex interactions between small molecules and drug targets, a crucial area for drug discovery. Additionally, his proficiency in cell biology and molecular biology techniques, such as cell culture, gene expression analysis, and protein assays, allows him to delve deep into the cellular mechanisms underlying cancer progression. Professor Yu’s lab also employs cutting-edge computational tools to predict drug-target interactions and evaluate the therapeutic potential of natural compounds. Furthermore, his extensive experience with bioinformatics allows for the integration of large-scale biological data, which is essential for identifying potential therapeutic pathways and developing novel cancer drugs. His skills in both experimental and computational research make him a leading figure in his field.

Awards and Honors

Professor Haiyang Yu has received numerous accolades for his groundbreaking contributions to cancer research and traditional Chinese medicine. He has been recognized for his leadership in national research projects, successfully leading six such initiatives that have received considerable funding. His outstanding scholarly work has earned him a reputation as a leading expert in his field, culminating in invitations to present at international conferences and contribute to high-impact journals. His publication record, which includes over 40 papers in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology, underscores his standing within the scientific community. These honors not only reflect his individual achievements but also highlight his capacity to drive scientific innovation in pharmacology and oncology. Professor Yu’s ongoing contributions continue to shape the direction of research in cancer therapies and natural product pharmacology.

Conclusion

Professor Haiyang Yu is an exceptional candidate for recognition as a Best Researcher. With a solid educational background, extensive professional experience, and a significant body of research publications, he has established himself as a leader in the field of cancer research and traditional Chinese medicine. His work in identifying novel anti-tumor mechanisms through natural products and network pharmacology has the potential to revolutionize cancer therapy. His leadership in national research projects, combined with his innovative research methods, has led to significant advancements in the understanding of cancer and drug discovery. As an academic and researcher, Professor Yu continues to push the boundaries of pharmacology, integrating traditional wisdom with modern scientific methodologies. His achievements reflect both personal excellence and a broader commitment to the advancement of cancer research, making him a deserving candidate for the Best Researcher Award.

Publication Top Notes

  1. Title: Autocrine and paracrine LIF signals to collaborate sorafenib-resistance in hepatocellular carcinoma and effects of Kanglaite Injection
    Authors: Shao, Y., Pu, W., Su, R., Han, L., Yu, H.
    Year: 2025
  2. Title: Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
    Authors: Bao, R., Chen, B., Wang, A., Zhang, Y., Wang, T.
    Year: 2025
  3. Title: Immunometabolism in cancer: basic mechanisms and new targeting strategy
    Authors: Su, R., Shao, Y., Huang, M., Yu, H., Qiu, Y.
    Year: 2024
    Citations: 4
  4. Title: Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells
    Authors: Lin, Y.-S., Sun, Z., Shen, L.-S., Chen, S., Chen, G.-Q.
    Year: 2024
    Citations: 6
  5. Title: Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma
    Authors: Liu, C., Lin, X., Huang, M., Qiu, Y., Yu, H.
    Year: 2024
    Citations: 2
  6. Title: Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models
    Authors: Chen, Z., Lu, J., Zhao, X.-M., Yu, H., Li, C.
    Year: 2024
  7. Title: Repurposing cyclovirobuxine D as a novel inhibitor of colorectal cancer progression via modulating the CCT3/YAP axis
    Authors: Liu, Y., Chen, L., Wang, J., Wang, T., Yu, H.
    Year: 2024
  8. Title: The role of NCAPH in cancer treatment
    Authors: Liu, C., Han, X., Zhang, S., Pu, W., Yu, H.
    Year: 2024
  9. Title: Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway
    Authors: Sheng, Y., Meng, G., Zhang, M., Wang, Y., Jiang, M.
    Year: 2024
    Citations: 2
  10. Title: Natural products with anti-tumorigenesis potential targeting macrophage
    Authors: Liu, H., Huang, M., Xin, D., Yu, H., Pu, W.
    Year: 2024

 

Na Zhang | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Na Zhang | Pharmaceutical Science | Best Researcher Award

Shandong university, China.

Dr. Na Zhang is a distinguished professor at the Institute of Pharmaceutics, Shandong University, China. She earned her Ph.D. in Pharmaceutics from China Pharmaceutical University in July 2004, following her Master’s and Bachelor’s degrees in Pharmacy from Shandong Medical University. Over her extensive career, Dr. Zhang has made significant contributions to the field of pharmaceutics, focusing on innovative drug delivery systems and cancer therapies. With over two decades of academic and research experience, she has established herself as a leader in her field, exemplified by her role as Associate Dean of the School of Pharmaceutical Science. Dr. Zhang’s research has garnered international recognition through numerous publications in high-impact journals, collaborative projects, and successful funding grants. She is dedicated to advancing pharmaceutical education while actively engaging in cutting-edge research that addresses critical healthcare challenges.

Professional Profile

Education

Dr. Na Zhang completed her Ph.D. in Pharmaceutics at the School of Pharmacy, China Pharmaceutical University, in July 2004. Prior to that, she obtained her Master’s degree in Pharmacy in July 1995 from Shandong Medical University, and her Bachelor’s degree in Pharmacy from the same institution in July 1992. Her educational journey has laid a solid foundation for her expertise in pharmaceutics, equipping her with the knowledge and skills to excel in both research and academic settings. Throughout her studies, Dr. Zhang has consistently demonstrated a commitment to academic excellence and innovation, which is evident in her subsequent professional achievements. Her comprehensive educational background enables her to contribute significantly to the fields of drug delivery systems and cancer immunotherapy, fostering the development of advanced pharmaceutical solutions that address pressing health issues.

Professional Experience

Dr. Na Zhang has a robust professional background spanning over two decades in academia and research. Since January 2013, she has served as a professor and Associate Dean at the School of Pharmaceutical Science, Shandong University. Prior to this, she held various positions, including Associate Professor and lecturer at Shandong University and a postdoctoral fellowship at the University of Kansas. Dr. Zhang’s career trajectory illustrates her dedication to the advancement of pharmaceutical sciences through teaching, research, and leadership. Her roles have involved mentoring students and researchers, developing curricula, and contributing to institutional governance. Dr. Zhang’s extensive experience in academia enables her to bridge the gap between scientific research and education, ensuring that her students are well-prepared for future challenges in the pharmaceutical industry.

Research Interests

Dr. Na Zhang’s research interests encompass a wide range of areas within pharmaceutics, particularly focusing on innovative drug delivery systems. She specializes in nano-drug delivery systems, exploring stimuli-responsive carriers for targeted therapy, and cancer immunotherapy. Her work on small molecule-based nanodrugs aims to enhance the efficacy and safety of cancer treatments, addressing critical challenges in current therapeutic approaches. Additionally, she engages in pre-clinical biopharmaceutical evaluation to assess the pharmacokinetics and dynamics of her developed formulations. By combining her expertise in nanotechnology and pharmaceutical sciences, Dr. Zhang seeks to contribute significantly to the field, improving treatment outcomes for patients with cancer and other complex diseases.

Research Skills

Dr. Na Zhang possesses a diverse array of research skills that enhance her effectiveness as a scientist and educator. Her expertise includes the design and development of nano-drug delivery systems, with a particular focus on creating stimuli-responsive carriers. She is proficient in pre-clinical biopharmaceutical evaluation, which involves assessing the pharmacological and therapeutic properties of new drug formulations. Additionally, Dr. Zhang has extensive experience in experimental design, data analysis, and scientific writing, which are essential for conducting high-quality research and publishing in reputable journals. Her collaborative approach fosters interdisciplinary partnerships, enhancing her research’s impact and relevance. Furthermore, her leadership in academic settings enables her to mentor aspiring researchers, sharing her knowledge and skills to cultivate the next generation of pharmaceutical scientists.

Awards and Honors

Dr. Na Zhang’s outstanding contributions to pharmaceutical sciences have earned her numerous awards and honors throughout her career. She has been recognized for her innovative research in nano-drug delivery and cancer immunotherapy, reflecting her commitment to advancing healthcare solutions. Her research has garnered prestigious funding from national bodies, highlighting the significance of her work in the field. Furthermore, Dr. Zhang has received accolades for her excellence in teaching and mentoring, demonstrating her dedication to fostering academic growth among her students. As a published author in high-impact journals, she has received recognition from peers and the broader scientific community for her contributions to advancing pharmaceutical knowledge. Her achievements underscore her influence as a researcher and educator in the pharmaceutical sciences.

Conclusion:

Dr. Na Zhang stands out as an exemplary candidate for the Best Researcher Award due to her significant contributions to pharmaceutical sciences, particularly in nano-drug delivery and cancer immunotherapy. Her impressive publication record, successful acquisition of research funding, and commitment to education reflect her dedication and impact in the field. By addressing the areas for improvement, Dr. Zhang can further enhance her influence and leadership within the global research community. Thus, she is highly deserving of this recognition.

Publications Top Notes

  1. Glypican-3-targeted macrophages delivering drug-loaded exosomes offer efficient cytotherapy in mouse models of solid tumours
    • Authors: Liu, J., Zhao, H., Gao, T., Zhang, N., Liu, Y.
    • Year: 2024
  2. Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC
    • Authors: Yang, H., Mu, W., Yuan, S., Liu, Y., Zhang, N.
    • Year: 2024
  3. Delivery Strategy to Enhance the Therapeutic Efficacy of Liver Fibrosis via Nanoparticle Drug Delivery Systems
    • Authors: Liu, J., Liu, J., Mu, W., Liu, Y., Zhang, N.
    • Year: 2024
    • Citations: 1
  4. In Situ Hydrogel Modulates cDC1-Based Antigen Presentation and Cancer Stemness to Enhance Cancer Vaccine Efficiency
    • Authors: Gao, T., Yuan, S., Liang, S., Zhang, N., Liu, Y.
    • Year: 2024
  5. Nano-Regulator Inhibits Tumor Immune Escape via the “Two-Way Regulation” Epigenetic Therapy Strategy
    • Authors: Liang, S., Liu, M., Mu, W., Jiang, D., Zhang, N.
    • Year: 2024
    • Citations: 3
  6. Cell Membrane Biomimetic Nano-Delivery Systems for Cancer Therapy
    • Authors: Xia, Z., Mu, W., Yuan, S., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 2
  7. Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy
    • Authors: Xia, Y., Fu, S., Ma, Q., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 30
  8. Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling
    • Authors: Fu, S., Chang, L., Liu, S., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 32
  9. Corrigendum to “In-situ self-assembled vaccine constructed with dual switchable nanotransformer for tumor immunotherapy”
    • Authors: Zhang, Z., Liang, S., Fu, S., Liu, Y., Zhang, N.
    • Year: 2023
  10. Macrophage-camouflaged epigenetic nanoinducers enhance chemoimmunotherapy in triple negative breast cancer
  • Authors: Gao, T., Sang, X., Huang, X., Liu, Y., Zhang, N.
  • Year: 2023
  • Citations: 3